Clinical trials: Immune System Suppression
HIV Infection, HIV Infections
Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
The aim of this study is to measure the prevention of lipoatrophy in patients treated with Lopinavir/R in monotherapy versus ZDV + 3TC + ABC
- Trial name
- KALIPO (NCT00865475)
- Testing
- AZT+3TC+ABV (Trizivir), Switching to LPV/r monotherapy (Kaletra)
- Where
- 7 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundacion SEIMC-GESIDA
Renal Transplantation, Immunosuppression
Renal Transplantation With Immune Monitoring
The aim of this observational study is to evaluate an FDA approved immune system monitoring assay (Immunknow, Cylex Inc. Columbia, MD) in renal transplant recipients using standard immunosuppression and prophylaxis protocols from…
- Trial name
- NCT00419575
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
Transplant, Adaptive Immunity
CNTRP POSITIVE Study
Adequate control of immunosuppression is critical in preventing graft failure after solid organ transplantation (SOT) and in avoiding life-threatening viral and malignant complications.
- Conditions
- Transplant, Adaptive Immunity, EBV, Medication Adherence
- Trial name
- NCT02318030
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- The Hospital for Sick Children
Focal Glomerulosclerosis
Sirolimus for Focal Segmental Glomerulosclerosis
This study will determine the safety and effectiveness of sirolimus (Rapamune® (Registered Trademark)) in treating focal segmental glomerulosclerosis (FSGS), a disease involving kidney scarring and increased protein in the urine.
- Trial name
- NCT00040508
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections
Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression
We hypothesize that a simple bridging ARV regimen that tends to select for virus with a low replicative capacity may tend to stabilize CD4 cell counts and HIV viral load and might be an option to consider in patients with MDR…
- Trial name
- NCT00336778
- Testing
- 3TC, TDF, NLV
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
Kidney Transplantation
Bela 8 Week Dosing
The purpose of this study is to transition patients who have been stable on Belatacept for one year after kidney transplant from standard 4-week to an investigational 8-week belatacept dosing schedule.
- Trial name
- NCT02560558
- Testing
- Belatacept
- Where
- 2 sites in United States
- Volunteers
- 166 people
- Sponsor
- Emory University
Leukoplakia, Hairy, HIV Infections
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL).
- Trial name
- NCT00002026
- Testing
- Acyclovir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Type 1 Diabetes
Alemtuzumab Induction in Islet Transplantation
Our experience suggests that further research with alemtuzumab is attractive in islet transplantation. Therefore, in this study we propose to combine alemtuzumab induction pre-transplant, with tacrolimus and mycophenolate mofetil…
- Trial name
- NCT00175253
- Testing
- alemtuzumab, islet transplant
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Alberta
Kidney Failure, Transplant Recipient (Kidney)
Tolerance Through Mixed Chimerism (Sip-Tego)
This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft.
- Conditions
- Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion
- Trial name
- NCT06972069
- Testing
- Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Tatsuo Kawai, MD, PhD
Septic Shock
Innate Lymphoid Cells in Septic Shock
Less than ten years after their intial description, the comprehension of Innate Lymphoid Cells (ILCs) biology is rapidly improving.
- Trial name
- CriSIs (NCT03297203)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HIV/AIDS
"Switch Either Near Suppression Or THOusand"
This trial addresses the question of the viral load (VL) threshold for switching from first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold at 1000 copies/mL.
- Trial name
- SESOTHO (NCT03088241)
- Testing
- switch
- Where
- 8 sites in Lesotho
- Volunteers
- 80 people
- Sponsor
- Niklaus Labhardt
Kidney Transplantation
A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection
To compare how well the new formulation of Tacrolimus® used once daily, in combination with other drugs helps prevent the rejection of a new kidney after transplantation compared to the twice daily dose of Tacrolimus
- Trial name
- OSAKA (NCT00717470)
- Testing
- Prograf®, Advagraf®, Mycophenolate Mofetil
- Where
- 110 sites in Argentina, Austria and 20 more
- Volunteers
- 1,252 people
- Sponsor
- Astellas Pharma Inc
Cytomegalovirus Infections
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal…
- Trial name
- (PREVAIL-KT) (NCT07430683)
- Testing
- Valganciclovir Prophylaxis, Preemptive Therapy (CMV PCR Monitoring)
- Where
- Mexico
- Volunteers
- 68 people
- Sponsor
- University of Guadalajara
Kidney Transplantation
The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus
The purpose of this study is to understand whether the pharmacokinetics of tacrolimus is influenced by the concurrent use of sirolimus.
- Trial name
- NCT00166829
- Testing
- sirolimus, tacrolimus, mycophenolate mofetil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Kidney Transplant
Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
The purpose of this study is to determine if one drug is superior to another with regard to safety and the preservation of renal function after a kidney transplant.
- Trial name
- NCT00137345
- Testing
- sirolimus
- Where
- 82 sites in United States, Argentina and 19 more
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Lupus Erythematosus, Systemic
Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus
The aim of this study is to compare the immunological efficacy of two pneumococcal vaccination strategies in patients with systemic lupus erythematosus (SLE) treated with corticosteroids associated or not with other…
- Trial name
- VACCILUP (NCT00611663)
- Testing
- Prevenar® and Pneumo23®
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Lung Transplant Recipients, Diverticulitis
Epidemiology of Diverticulitis in Lung Transplant Recipients
The purpose of this study is to assess incidence, treatment modalities and outcome of complicated and uncomplicated diverticulitis in highly immunosuppressed lung transplant recipients (LTRs) in order to establish improved…
- Trial name
- NCT02132078
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Atopic Dermatitis
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis
- Trial name
- 0405-01-04 (NCT01232543)
- Testing
- Product 0405
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Fougera Pharmaceuticals Inc.
End Stage Renal Disease, Rejection of Renal Transplant
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
The overall aim of the study is to prospectively investigate the impact of two maintenance calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and twice-daily tacrolimus on subpopulations of T…
- Trial name
- NCT03289650
- Testing
- Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Lorenzo Gallon